Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Reaches New 12-Month High - Should You Buy?

Key Points

• Bayer shares rose 5.8% to a new 52-week high of $15.24 amid improved business outlook.
• The company raised its 2026 profit outlook, citing stronger pharmaceutical performance and demand for medicines including Nubeqa and Kerendia, despite pressures in agriculture and consumer health.
• Q3 results were mixed: revenue of $11.25 billion topped estimates, while EPS of $0.11 missed the $0.13 consensus. Analysts’ overall rating is “Buy.”

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) hit a new 52-week high during mid-day trading on Wednesday. The stock traded as high as $15.24 and last traded at $15.2270, with a volume of 978,158 shares. The stock had previously closed at $14.41.

Key Bayer Aktiengesellschaft News

Here are the key news stories impacting Bayer Aktiengesellschaft this week:

• Positive Sentiment: Bayer raised its 2026 profit outlook as recovering pharmaceutical performance and strong demand for key medicines helped counter market pressures in agriculture and consumer health. Growth in Nubeqa and Kerendia was also highlighted. Reuters: Bayer raises 2026 profit outlook Zacks: Q3 earnings and revenues miss estimates, pharma performs well
• Positive Sentiment: The company is seeking a larger position in Latin America’s fast-growing biologicals market, offering a potential longer-term growth opportunity, though the report does not describe a specific deal. Reuters: Bayer seeks bigger role in Latin American biologicals market
• Neutral Sentiment: Q3 revenue of $11.25 billion narrowly exceeded analyst expectations of $11.21 billion, but EPS of $0.11 fell short of the $0.13 consensus. The mixed results may be outweighed by the improved outlook. MarketBeat: Bayer quarterly results
• Neutral Sentiment: Bayer plans to present cardiovascular, kidney and stroke research at the American Heart Association’s November scientific sessions. The data could inform future pipeline prospects, but the presentations are not yet evidence of commercial impact. Bayer: New data at 2026 AHA Scientific Sessions

Analyst Ratings Changes

Separately, Zacks Research upgraded Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Friday, July 10th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy".

Bayer Aktiengesellschaft Trading Up 5.8%

The firm's 50-day simple moving average is $13.43 and its 200 day simple moving average is $12.56. The stock has a market cap of $59.89 billion, a P/E ratio of -29.88, a PEG ratio of 2.11 and a beta of 0.57. The company has a current ratio of 1.04, a quick ratio of 0.67 and a debt-to-equity ratio of 1.05.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.02). Bayer Aktiengesellschaft had a positive return on equity of 16.77% and a negative net margin of 3.80%. The business had revenue of $11.25 billion for the quarter, compared to analyst estimates of $11.21 billion. As a group, equities research analysts anticipate that Bayer Aktiengesellschaft will post 1.27 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott, the company develops products in health care and agriculture and serves customers in markets around the world.

Bayer operates through three primary businesses: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals segment develops prescription medicines in areas such as cardiovascular disease, women's health, oncology, hematology and specialty therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.